WO2004038416A8 - Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6) - Google Patents

Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)

Info

Publication number
WO2004038416A8
WO2004038416A8 PCT/EP2003/011394 EP0311394W WO2004038416A8 WO 2004038416 A8 WO2004038416 A8 WO 2004038416A8 EP 0311394 W EP0311394 W EP 0311394W WO 2004038416 A8 WO2004038416 A8 WO 2004038416A8
Authority
WO
WIPO (PCT)
Prior art keywords
gpr6
disorders
human
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2003/011394
Other languages
English (en)
Other versions
WO2004038416A1 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to AU2003274005A priority Critical patent/AU2003274005A1/en
Publication of WO2004038416A1 publication Critical patent/WO2004038416A1/fr
Publication of WO2004038416A8 publication Critical patent/WO2004038416A8/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un récepteur GPR6 humain qui est associé aux maladies hématologiques, aux maladies cardiovasculaires, aux troubles du système nerveux central et périphérique, aux affections urologiques, aux troubes gastro-entérologiques, aux inflammations et au cancer. L'invention se rapporte également à des analyses permettant l'identification de composés utiles pour le traitement et la prévention des maladies hématologiques, des maladies cardiovasculaires, des troubles du système nerveux central et périphérique, des affections urologiques, des troubes gastro-entérologiques, des inflammations et du cancer. L'invention porte enfin sur des composés qui se lient au GPR6 et/ou stimulent ou inhibent l'activité du GPR6, et sur des compositions pharmaceutiques renfermant lesdits composés.
PCT/EP2003/011394 2002-10-24 2003-10-15 Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6) WO2004038416A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274005A AU2003274005A1 (en) 2002-10-24 2003-10-15 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2376902A 2002-10-24 2002-10-24
US02023769.9 2002-10-24

Publications (2)

Publication Number Publication Date
WO2004038416A1 WO2004038416A1 (fr) 2004-05-06
WO2004038416A8 true WO2004038416A8 (fr) 2005-03-17

Family

ID=32174049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011394 WO2004038416A1 (fr) 2002-10-24 2003-10-15 Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)

Country Status (2)

Country Link
AU (1) AU2003274005A1 (fr)
WO (1) WO2004038416A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1071766A4 (fr) * 1998-03-23 2004-12-29 Smithkline Beecham Corp PROTEINE G HUMAINE COUPLEE AU RECEPTEUR GPR6sb
JP2004515449A (ja) * 1999-02-26 2004-05-27 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 第６ｇタンパク質共役型受容体の小分子調節物質

Also Published As

Publication number Publication date
AU2003274005A1 (en) 2004-05-13
WO2004038416A1 (fr) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2003074069A3 (fr) Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2003065044A8 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2004042405A3 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004015422A3 (fr) Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire
WO2004015427A3 (fr) Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2004048978A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37)
WO2004038406A3 (fr) Diagnostic et therapie de maladies associees au recepteur 42 couple a la proteine g (gpr42) humain
WO2004038408A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur humain 14 couple a la proteine g (gpr14)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005040790A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 75 couple a la proteine g (gpr75)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II)) FOR ALL DESIGNATED STATES EXCEPT US."

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP